 Trisenox was shown to be effective in a pivotal trial consisting of 40 subjects, ages 5 to 72, at a nine-institution multi-center trial led by Memorial Sloan-Kettering Cancer Center. With Trisenox, 70 of the subjects achieved a complete remission, and 79 of the complete responders achieved a molecular remission as measured by reverse transcriptase-polymerase chain reaction RT-PCR. Complete remission was achieved on average within two months after initiation of Trisenox. Sixty-eight percent of subjects who achieved complete remission were still alive and 58 were disease free, at a median follow-up time of 16 months. 